Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2131 to 2145 of 9102 results

  1. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    In development Reference number: GID-TA11116 Expected publication date:  11 November 2026

    Technology appraisal guidance
    In development

  2. Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

    Awaiting development Reference number: GID-TA11092 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Camizestrant as an add-on to a first-line CDK4/6 inhibitor for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation [ID6535]

    Awaiting development Reference number: GID-TA11687 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Baloxavir marboxil for treating influenza in people 12 years and over at high risk of complications [ID3794]

    Awaiting development Reference number: GID-TA10683 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Filgotinib for treating axial spondyloarthritis [ID6594]

    In development Reference number: GID-TA11776 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Doravirine–islatravir for treating HIV-1 in people with virological suppression on bictegravir, emtricitabine and tenofovir alafenamide combination treatment

    Awaiting development Reference number: GID-TA11735 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Doravirine-islatravir for previously untreated HIV-1 infection

    Awaiting development Reference number: GID-TA11734 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Doravirine–islatravir for treating HIV-1 in people with virological suppression on antiretroviral therapy

    Awaiting development Reference number: GID-TA11736 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. MK-3000 for treating diabetic macular oedema

    Awaiting development Reference number: GID-TA12473 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    Awaiting development Reference number: GID-TA11303 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Veligrotug for treating thyroid eye disease [ID6636]

    Awaiting development Reference number: GID-TA11839 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Elacestrant with everolimus for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6753]

    Awaiting development Reference number: GID-TA11973 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732]

    In development Reference number: GID-TA11959 Expected publication date:  17 June 2027

    Technology appraisal guidance
    In development

  14. Enlicitide decanoate for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6656]

    Awaiting development Reference number: GID-TA11871 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

    In development Reference number: GID-TA11772 Expected publication date: TBC

    Technology appraisal guidance
    In development